Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 05, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On January 4, 2005, Abacus (GSK) Trustees Limited transferred 48,800 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on January 5, 2005.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold an interest in the shares held by the trust in the same manner as other employees.
Key Facts for Investor Verification
- 48,800 Ordinary Shares were transferred from the GSK Trust to employee plan participants on January 4, 2005.
- Directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe have an indirect interest in the GSK Trust shares.
- This filing does not contain financial results; investors should refer to the company's Form 20-F for financial data.